clinical trial · NCT07704658
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
NSCLC (Non-small Cell Lung Cancer)Thyroid CancerSolid Tumor MalignanciesAdvanced MalignanciesPralsetinibCYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
brief summary
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
started
Mar 4, 2026
primary completion
Jul 30, 2027
completion
Aug 30, 2027
last updated
Aug 10, 2026
official title
A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol/Norethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol